logo
logo

Mendus Ab: Mendus Announces Financing Commitments Totaling Up To Sek 250 Million With Van Herk Investments And Negma Group

Aug 26, 2022•almost 3 years ago
Paris

Description

Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company addressing tumor recurrence through cell-based immunotherapies, today announces that it has entered into a binding agreement for a financing commitment of up to SEK 200 million (“Transaction”) with Negma Group Ltd, a Paris-based leading financial institution (“Negma”). The Company has also entered into a binding commitment letter to receive a shareholder loan up to SEK 50 million with its existing shareholder Van Herk Investments.

Company Information

Company

Mendus

Location

Paris, Texas, United States

About

Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company addressing tumor recurrence through cell-based immunotherapies, today announces that it has entered into a binding agreement for a financing commitment of up to SEK 200 million (“Transaction”) with Negma Group Ltd, a Paris-based leading financial institution (“Negma”). The Company has also entered into a binding commitment letter to receive a shareholder loan up to SEK 50 million with its existing shareholder Van Herk Investments.

FundzWatch™ Score

64
Medium Activity

Buyer Intent Analysis

Get personalized insights on buying likelihood

Related People